A Once-Daily Topical Agent With a Novel Mechanism of Action and Efficacy Advantages Over Elidel Would Earn Higher Patient Share in the U.S. Than in Europe, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that high and super-high potency topical corticosteroids (TCSs) will remain Decision Resources' proprietary clinical gold standard through 2017 for the treatment of atopic dermatitis. While some therapies in development for the disease hold promise, most have efficacy, safety and tolerability and/or delivery issues.
"Although efficacious drugs like high and super-high potency TCSs are available, they are predominantly used to treat adult patients with severe atopic dermatitis," stated Kyle Crowell, analyst at Decision Resources. "For pediatric and adult patients with less severe atopic dermatitis, physicians prefer to prescribe drugs with superior safety profiles. Improvements in safety and tolerability would provide a competitive advantage for an emerging atopic dermatitis drug."
The new report entitled Atopic Dermatitis: A Market with Well-Established First-Line Agents Still Needs a Safe Maintenance Therapy also finds that a once-daily topical agent with a novel mechanism of action and efficacy advantages over Novartis' Elidel would earn 35 percent patient share in the atopic dermatitis drug market, according to surveyed U.S. dermatologists. On the other hand, in Europe, such an agent would earn a 25 percent patient share, according to surveyed European dermatologists.
About the Report
Atopic Dermatitis: A Market with Well-Established First-Line Agents Still Needs a Safe Maintenance Therapy is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-dept
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved